The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Validation of a 16-gene signature for prediction of recurrence after nephrectomy in stage I-III clear cell renal cell carcinoma (ccRCC).
Bernard J. Escudier
Research Funding - Genomic Health
Serge Koscielny
Research Funding - Genomic Health
Margarita Lopatin
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Christer Svedman
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Virginie Verkarre
Research Funding - Genomic Health
Camelia Radulescu
Research Funding - Genomic Health
Yann Neuzillet
Research Funding - Genomic Health
Isabelle Hemmerlé
Research Funding - Genomic Health
Marc Olivier Timsit
Research Funding - Genomic Health
Athanasios C. Tsiatis
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Michael Bonham
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Dejan Knezevic
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Thierry Lebret
Research Funding - Genomic Health
Audrey D. Goddard
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Mejean Arnaud
Research Funding - Genomic Health